Loading…

Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adults

The vicious cycle hypothesis for bronchiectasis predicts that bacterial colonisation of the respiratory tract perpetuates inflammatory change. This damages the mucociliary escalator, preventing bacterial clearance and allowing persistence of pro-inflammatory mediators. Conventional treatment with ph...

Full description

Saved in:
Bibliographic Details
Published in:Cochrane database of systematic reviews 2015-08, Vol.2015 (8), p.CD001392, Article CD001392
Main Authors: Hnin, Khin, Nguyen, Chau, Carson, Kristin V, Evans, David J, Greenstone, Michael, Smith, Brian J
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c5263-944ce295825c7e381dc421cb124c6d71b271f78bf10242ea4f5aebbf7c885bd83
cites
container_end_page
container_issue 8
container_start_page CD001392
container_title Cochrane database of systematic reviews
container_volume 2015
creator Hnin, Khin
Nguyen, Chau
Carson, Kristin V
Evans, David J
Greenstone, Michael
Smith, Brian J
description The vicious cycle hypothesis for bronchiectasis predicts that bacterial colonisation of the respiratory tract perpetuates inflammatory change. This damages the mucociliary escalator, preventing bacterial clearance and allowing persistence of pro-inflammatory mediators. Conventional treatment with physiotherapy and intermittent antibiotics is believed to improve the condition of people with bronchiectasis, although no conclusive data show that these interventions influence the natural history of the condition. Various strategies have been tried to interrupt this cycle of infection and inflammation, including prolonging antibiotic treatment with the goal of allowing the airway mucosa to heal. To determine the benefits of prolonged antibiotic therapy in the treatment of patients with bronchiectasis. We searched the Cochrane Airways Group Trials Register and reference lists of identified articles. Searches were current as of February 2014. Randomised trials examining the use of prolonged antibiotic therapy (for four or more weeks) in the treatment of bronchiectasis compared with placebo or usual care. Two review authors independently assessed trial quality and extracted data. We contacted study authors to ask for missing information. Eighteen trials met the inclusion criteria, randomly assigning a total of 1157 participants. Antibiotics were given for between four weeks and 83 weeks. Limited meta-analysis was possible because of the diversity of outcomes reported in these trials. Based on the number of participants with at least one exacerbation, the meta-analysis showed significant effects in favour of the intervention (odds ratio (OR) 0.31, 95% confidence interval (CI) 0.19 to 0.52; P value < 0.00001), with events occurring in 271 per 1000 people in the intervention arm (95% CI 126 to 385) and in 546 per 1000 in the control population, based on evidence of moderate quality. A non-statistically significant reduction in hospitalisation favoured the use of prolonged antibiotics with a moderate quality grade of supporting evidence (37 per 1000 in the intervention arm (95% CI 13 to 96) and 87 per 1000 in control (OR 0.40, 95% CI 0.14 to 1.11; P value = 0.08). Drug resistance developed in 36 of 220 participants taking antibiotics compared with 10 of 211 participants given placebo or standard therapy (OR 3.48, 95% CI 1.20 to 10.07; P value = 0.02), translating to natural frequencies of 155 per 1000 in the intervention arm (95% CI 59 to 346) and 50 per 1000 in the c
doi_str_mv 10.1002/14651858.cd001392.pub3
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6483474</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1708902577</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5263-944ce295825c7e381dc421cb124c6d71b271f78bf10242ea4f5aebbf7c885bd83</originalsourceid><addsrcrecordid>eNpVUV1LwzAUDaK4Of0Lo4--dOarTQoiiPgFAwUVfAtJmm6RLplJK-zfm7JN5tO9h3vuOck9AEwRnCEI8RWiZYF4wWe6hhCRCs_WvSJHYJwGVU4r8nl80I_AWYxfEJIKIX4KRrjEDJYYjsHba_CtdwtTZ9J1VlnfWR2zxofMeZfrTUw4a6wKPtqYpeL00hrdyQFalyXU1sG4tJ4k6r7t4jk4aWQbzcWuTsDHw_373VM-f3l8vrud57rAJckrSrXBVcFxoZkhHNWaYqQVwlSXNUMKM9QwrhoEMcVG0qaQRqmGac4LVXMyATdb3fT1lam1cV2QrVgHu5JhI7y04v_E2aVY-B9RUk4oo0ngcicQ_HdvYidWNmrTttIZ30eBGOQVxAVjiTo99Poz2V8yEa63BJ0uFYNphLad7KwfrG0rEBRDcGIfnNgHN7yRkF98bI2P</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1708902577</pqid></control><display><type>article</type><title>Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adults</title><source>Alma/SFX Local Collection</source><creator>Hnin, Khin ; Nguyen, Chau ; Carson, Kristin V ; Evans, David J ; Greenstone, Michael ; Smith, Brian J</creator><creatorcontrib>Hnin, Khin ; Nguyen, Chau ; Carson, Kristin V ; Evans, David J ; Greenstone, Michael ; Smith, Brian J</creatorcontrib><description>The vicious cycle hypothesis for bronchiectasis predicts that bacterial colonisation of the respiratory tract perpetuates inflammatory change. This damages the mucociliary escalator, preventing bacterial clearance and allowing persistence of pro-inflammatory mediators. Conventional treatment with physiotherapy and intermittent antibiotics is believed to improve the condition of people with bronchiectasis, although no conclusive data show that these interventions influence the natural history of the condition. Various strategies have been tried to interrupt this cycle of infection and inflammation, including prolonging antibiotic treatment with the goal of allowing the airway mucosa to heal. To determine the benefits of prolonged antibiotic therapy in the treatment of patients with bronchiectasis. We searched the Cochrane Airways Group Trials Register and reference lists of identified articles. Searches were current as of February 2014. Randomised trials examining the use of prolonged antibiotic therapy (for four or more weeks) in the treatment of bronchiectasis compared with placebo or usual care. Two review authors independently assessed trial quality and extracted data. We contacted study authors to ask for missing information. Eighteen trials met the inclusion criteria, randomly assigning a total of 1157 participants. Antibiotics were given for between four weeks and 83 weeks. Limited meta-analysis was possible because of the diversity of outcomes reported in these trials. Based on the number of participants with at least one exacerbation, the meta-analysis showed significant effects in favour of the intervention (odds ratio (OR) 0.31, 95% confidence interval (CI) 0.19 to 0.52; P value &lt; 0.00001), with events occurring in 271 per 1000 people in the intervention arm (95% CI 126 to 385) and in 546 per 1000 in the control population, based on evidence of moderate quality. A non-statistically significant reduction in hospitalisation favoured the use of prolonged antibiotics with a moderate quality grade of supporting evidence (37 per 1000 in the intervention arm (95% CI 13 to 96) and 87 per 1000 in control (OR 0.40, 95% CI 0.14 to 1.11; P value = 0.08). Drug resistance developed in 36 of 220 participants taking antibiotics compared with 10 of 211 participants given placebo or standard therapy (OR 3.48, 95% CI 1.20 to 10.07; P value = 0.02), translating to natural frequencies of 155 per 1000 in the intervention arm (95% CI 59 to 346) and 50 per 1000 in the control arm. The intervention was well tolerated with no overall significant difference in withdrawal between treatment and placebo groups (OR 0.91, 95% CI 0.56 to 1.49). Diarrhoea was commonly reported as an adverse event, particularly with an oral intervention. Available evidence shows benefit associated with use of prolonged antibiotics in the treatment of patients with bronchiectasis, at least halving the odds of exacerbation (with 275 fewer exacerbations per every 1000 people treated in the antibiotic arm compared with the control arm) and hospitalisation (50 fewer hospitalisations per 1000 people in the antibiotic arm compared with the control arm). However, the risk of emerging drug resistance is increased more than threefold. This review is limited by diversity of trials and by evidence of moderate to low quality. Further randomised controlled trials with adequate power and standardised end points are required.</description><identifier>ISSN: 1469-493X</identifier><identifier>EISSN: 1469-493X</identifier><identifier>DOI: 10.1002/14651858.cd001392.pub3</identifier><identifier>PMID: 26270620</identifier><language>eng</language><publisher>England: John Wiley &amp; Sons, Ltd</publisher><subject>Adult ; Anti-Bacterial Agents - administration &amp; dosage ; Anti-Bacterial Agents - adverse effects ; Bronchiectasis ; Bronchiectasis - drug therapy ; Bronchiectasis - microbiology ; Child ; Child health ; Diarrhea - chemically induced ; Disease Progression ; Drug Resistance, Bacterial ; Hospitalization - statistics &amp; numerical data ; Humans ; Lungs &amp; airways ; Middle Aged ; Odds Ratio ; Randomized Controlled Trials as Topic ; Time Factors</subject><ispartof>Cochrane database of systematic reviews, 2015-08, Vol.2015 (8), p.CD001392, Article CD001392</ispartof><rights>Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5263-944ce295825c7e381dc421cb124c6d71b271f78bf10242ea4f5aebbf7c885bd83</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26270620$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hnin, Khin</creatorcontrib><creatorcontrib>Nguyen, Chau</creatorcontrib><creatorcontrib>Carson, Kristin V</creatorcontrib><creatorcontrib>Evans, David J</creatorcontrib><creatorcontrib>Greenstone, Michael</creatorcontrib><creatorcontrib>Smith, Brian J</creatorcontrib><title>Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adults</title><title>Cochrane database of systematic reviews</title><addtitle>Cochrane Database Syst Rev</addtitle><description>The vicious cycle hypothesis for bronchiectasis predicts that bacterial colonisation of the respiratory tract perpetuates inflammatory change. This damages the mucociliary escalator, preventing bacterial clearance and allowing persistence of pro-inflammatory mediators. Conventional treatment with physiotherapy and intermittent antibiotics is believed to improve the condition of people with bronchiectasis, although no conclusive data show that these interventions influence the natural history of the condition. Various strategies have been tried to interrupt this cycle of infection and inflammation, including prolonging antibiotic treatment with the goal of allowing the airway mucosa to heal. To determine the benefits of prolonged antibiotic therapy in the treatment of patients with bronchiectasis. We searched the Cochrane Airways Group Trials Register and reference lists of identified articles. Searches were current as of February 2014. Randomised trials examining the use of prolonged antibiotic therapy (for four or more weeks) in the treatment of bronchiectasis compared with placebo or usual care. Two review authors independently assessed trial quality and extracted data. We contacted study authors to ask for missing information. Eighteen trials met the inclusion criteria, randomly assigning a total of 1157 participants. Antibiotics were given for between four weeks and 83 weeks. Limited meta-analysis was possible because of the diversity of outcomes reported in these trials. Based on the number of participants with at least one exacerbation, the meta-analysis showed significant effects in favour of the intervention (odds ratio (OR) 0.31, 95% confidence interval (CI) 0.19 to 0.52; P value &lt; 0.00001), with events occurring in 271 per 1000 people in the intervention arm (95% CI 126 to 385) and in 546 per 1000 in the control population, based on evidence of moderate quality. A non-statistically significant reduction in hospitalisation favoured the use of prolonged antibiotics with a moderate quality grade of supporting evidence (37 per 1000 in the intervention arm (95% CI 13 to 96) and 87 per 1000 in control (OR 0.40, 95% CI 0.14 to 1.11; P value = 0.08). Drug resistance developed in 36 of 220 participants taking antibiotics compared with 10 of 211 participants given placebo or standard therapy (OR 3.48, 95% CI 1.20 to 10.07; P value = 0.02), translating to natural frequencies of 155 per 1000 in the intervention arm (95% CI 59 to 346) and 50 per 1000 in the control arm. The intervention was well tolerated with no overall significant difference in withdrawal between treatment and placebo groups (OR 0.91, 95% CI 0.56 to 1.49). Diarrhoea was commonly reported as an adverse event, particularly with an oral intervention. Available evidence shows benefit associated with use of prolonged antibiotics in the treatment of patients with bronchiectasis, at least halving the odds of exacerbation (with 275 fewer exacerbations per every 1000 people treated in the antibiotic arm compared with the control arm) and hospitalisation (50 fewer hospitalisations per 1000 people in the antibiotic arm compared with the control arm). However, the risk of emerging drug resistance is increased more than threefold. This review is limited by diversity of trials and by evidence of moderate to low quality. Further randomised controlled trials with adequate power and standardised end points are required.</description><subject>Adult</subject><subject>Anti-Bacterial Agents - administration &amp; dosage</subject><subject>Anti-Bacterial Agents - adverse effects</subject><subject>Bronchiectasis</subject><subject>Bronchiectasis - drug therapy</subject><subject>Bronchiectasis - microbiology</subject><subject>Child</subject><subject>Child health</subject><subject>Diarrhea - chemically induced</subject><subject>Disease Progression</subject><subject>Drug Resistance, Bacterial</subject><subject>Hospitalization - statistics &amp; numerical data</subject><subject>Humans</subject><subject>Lungs &amp; airways</subject><subject>Middle Aged</subject><subject>Odds Ratio</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Time Factors</subject><issn>1469-493X</issn><issn>1469-493X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNpVUV1LwzAUDaK4Of0Lo4--dOarTQoiiPgFAwUVfAtJmm6RLplJK-zfm7JN5tO9h3vuOck9AEwRnCEI8RWiZYF4wWe6hhCRCs_WvSJHYJwGVU4r8nl80I_AWYxfEJIKIX4KRrjEDJYYjsHba_CtdwtTZ9J1VlnfWR2zxofMeZfrTUw4a6wKPtqYpeL00hrdyQFalyXU1sG4tJ4k6r7t4jk4aWQbzcWuTsDHw_373VM-f3l8vrud57rAJckrSrXBVcFxoZkhHNWaYqQVwlSXNUMKM9QwrhoEMcVG0qaQRqmGac4LVXMyATdb3fT1lam1cV2QrVgHu5JhI7y04v_E2aVY-B9RUk4oo0ngcicQ_HdvYidWNmrTttIZ30eBGOQVxAVjiTo99Poz2V8yEa63BJ0uFYNphLad7KwfrG0rEBRDcGIfnNgHN7yRkF98bI2P</recordid><startdate>20150813</startdate><enddate>20150813</enddate><creator>Hnin, Khin</creator><creator>Nguyen, Chau</creator><creator>Carson, Kristin V</creator><creator>Evans, David J</creator><creator>Greenstone, Michael</creator><creator>Smith, Brian J</creator><general>John Wiley &amp; Sons, Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20150813</creationdate><title>Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adults</title><author>Hnin, Khin ; Nguyen, Chau ; Carson, Kristin V ; Evans, David J ; Greenstone, Michael ; Smith, Brian J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5263-944ce295825c7e381dc421cb124c6d71b271f78bf10242ea4f5aebbf7c885bd83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Anti-Bacterial Agents - administration &amp; dosage</topic><topic>Anti-Bacterial Agents - adverse effects</topic><topic>Bronchiectasis</topic><topic>Bronchiectasis - drug therapy</topic><topic>Bronchiectasis - microbiology</topic><topic>Child</topic><topic>Child health</topic><topic>Diarrhea - chemically induced</topic><topic>Disease Progression</topic><topic>Drug Resistance, Bacterial</topic><topic>Hospitalization - statistics &amp; numerical data</topic><topic>Humans</topic><topic>Lungs &amp; airways</topic><topic>Middle Aged</topic><topic>Odds Ratio</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hnin, Khin</creatorcontrib><creatorcontrib>Nguyen, Chau</creatorcontrib><creatorcontrib>Carson, Kristin V</creatorcontrib><creatorcontrib>Evans, David J</creatorcontrib><creatorcontrib>Greenstone, Michael</creatorcontrib><creatorcontrib>Smith, Brian J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cochrane database of systematic reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hnin, Khin</au><au>Nguyen, Chau</au><au>Carson, Kristin V</au><au>Evans, David J</au><au>Greenstone, Michael</au><au>Smith, Brian J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adults</atitle><jtitle>Cochrane database of systematic reviews</jtitle><addtitle>Cochrane Database Syst Rev</addtitle><date>2015-08-13</date><risdate>2015</risdate><volume>2015</volume><issue>8</issue><spage>CD001392</spage><pages>CD001392-</pages><artnum>CD001392</artnum><issn>1469-493X</issn><eissn>1469-493X</eissn><abstract>The vicious cycle hypothesis for bronchiectasis predicts that bacterial colonisation of the respiratory tract perpetuates inflammatory change. This damages the mucociliary escalator, preventing bacterial clearance and allowing persistence of pro-inflammatory mediators. Conventional treatment with physiotherapy and intermittent antibiotics is believed to improve the condition of people with bronchiectasis, although no conclusive data show that these interventions influence the natural history of the condition. Various strategies have been tried to interrupt this cycle of infection and inflammation, including prolonging antibiotic treatment with the goal of allowing the airway mucosa to heal. To determine the benefits of prolonged antibiotic therapy in the treatment of patients with bronchiectasis. We searched the Cochrane Airways Group Trials Register and reference lists of identified articles. Searches were current as of February 2014. Randomised trials examining the use of prolonged antibiotic therapy (for four or more weeks) in the treatment of bronchiectasis compared with placebo or usual care. Two review authors independently assessed trial quality and extracted data. We contacted study authors to ask for missing information. Eighteen trials met the inclusion criteria, randomly assigning a total of 1157 participants. Antibiotics were given for between four weeks and 83 weeks. Limited meta-analysis was possible because of the diversity of outcomes reported in these trials. Based on the number of participants with at least one exacerbation, the meta-analysis showed significant effects in favour of the intervention (odds ratio (OR) 0.31, 95% confidence interval (CI) 0.19 to 0.52; P value &lt; 0.00001), with events occurring in 271 per 1000 people in the intervention arm (95% CI 126 to 385) and in 546 per 1000 in the control population, based on evidence of moderate quality. A non-statistically significant reduction in hospitalisation favoured the use of prolonged antibiotics with a moderate quality grade of supporting evidence (37 per 1000 in the intervention arm (95% CI 13 to 96) and 87 per 1000 in control (OR 0.40, 95% CI 0.14 to 1.11; P value = 0.08). Drug resistance developed in 36 of 220 participants taking antibiotics compared with 10 of 211 participants given placebo or standard therapy (OR 3.48, 95% CI 1.20 to 10.07; P value = 0.02), translating to natural frequencies of 155 per 1000 in the intervention arm (95% CI 59 to 346) and 50 per 1000 in the control arm. The intervention was well tolerated with no overall significant difference in withdrawal between treatment and placebo groups (OR 0.91, 95% CI 0.56 to 1.49). Diarrhoea was commonly reported as an adverse event, particularly with an oral intervention. Available evidence shows benefit associated with use of prolonged antibiotics in the treatment of patients with bronchiectasis, at least halving the odds of exacerbation (with 275 fewer exacerbations per every 1000 people treated in the antibiotic arm compared with the control arm) and hospitalisation (50 fewer hospitalisations per 1000 people in the antibiotic arm compared with the control arm). However, the risk of emerging drug resistance is increased more than threefold. This review is limited by diversity of trials and by evidence of moderate to low quality. Further randomised controlled trials with adequate power and standardised end points are required.</abstract><cop>England</cop><pub>John Wiley &amp; Sons, Ltd</pub><pmid>26270620</pmid><doi>10.1002/14651858.cd001392.pub3</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1469-493X
ispartof Cochrane database of systematic reviews, 2015-08, Vol.2015 (8), p.CD001392, Article CD001392
issn 1469-493X
1469-493X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6483474
source Alma/SFX Local Collection
subjects Adult
Anti-Bacterial Agents - administration & dosage
Anti-Bacterial Agents - adverse effects
Bronchiectasis
Bronchiectasis - drug therapy
Bronchiectasis - microbiology
Child
Child health
Diarrhea - chemically induced
Disease Progression
Drug Resistance, Bacterial
Hospitalization - statistics & numerical data
Humans
Lungs & airways
Middle Aged
Odds Ratio
Randomized Controlled Trials as Topic
Time Factors
title Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adults
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T12%3A20%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prolonged%20antibiotics%20for%20non-cystic%20fibrosis%20bronchiectasis%20in%20children%20and%20adults&rft.jtitle=Cochrane%20database%20of%20systematic%20reviews&rft.au=Hnin,%20Khin&rft.date=2015-08-13&rft.volume=2015&rft.issue=8&rft.spage=CD001392&rft.pages=CD001392-&rft.artnum=CD001392&rft.issn=1469-493X&rft.eissn=1469-493X&rft_id=info:doi/10.1002/14651858.cd001392.pub3&rft_dat=%3Cproquest_pubme%3E1708902577%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5263-944ce295825c7e381dc421cb124c6d71b271f78bf10242ea4f5aebbf7c885bd83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1708902577&rft_id=info:pmid/26270620&rfr_iscdi=true